The UK and US have signed a important trade agreement that will preserve no import taxes on British medicine exports being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the public health system. This pledge secures that tariffs on these key exports will stay at nothing for a period of three years.
This development comes after earlier warnings to significantly raise duties on patented pharmaceutical products, with increases discussed up to double the cost.
"This deal with the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to American-British medicine commerce," an announcement said.
Commercial Significance
Pharmaceuticals constitute one of the UK's most significant exports to the US, which is easily the largest market for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of last September, the UK exported pharmaceutical products valued at billions to the US. This value made up 17.4% of total UK exports in that period.
"This guarantee secures employment, increases funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Key British Pledges
The pact includes several key commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to double overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates topped 20%.
Industry Background
This agreement follows a ongoing row between the drug companies and the British authorities over spending levels and regulatory access.
These tensions were heightened by claims that US customers were charged several times more for the same drugs than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had shrunk as a share of its resources over the past decade.
